SLC6A20

Across TCGA pan-cancer cohorts, SLC6A20 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SLC6A20 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC6A20 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC6A20 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

STAD, PRAD, and SKCM are the cancer types where SLC6A20 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.812	0.551	.014	6	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
COAD	OS	Median	II,III,IV	0.171	0.651	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SLC6A20–STAD (OS)

Open the STAD breakdown →